{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:50:12Z","timestamp":1794257412912,"version":"4.9.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.annonc.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T11:38:49Z","timestamp":1743680329000},"page":"796-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial"],"prefix":"10.1016","volume":"36","author":[{"given":"L.","family":"Bergmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Boleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-O.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ivanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fl\u00f6rcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Priou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Deckbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Burkholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.annonc.2025.03.016_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.016_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor\u2013based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.annonc.2025.03.016_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part a: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.annonc.2025.03.016_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000495366","article-title":"Non-clear cell renal cell carcinoma \u2013 pathology and treatment options","volume":"42","author":"Ahrens","year":"2019","journal-title":"Oncol Res Treat"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.016_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2014.05.010","article-title":"Systemic therapy for non\u2013clear cell renal cell carcinomas: a systematic review and meta-analysis","volume":"67","author":"Vera-Badillo","year":"2015","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.annonc.2025.03.016_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/14737140.2021.1959319","article-title":"Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview","volume":"21","author":"Bergmann","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"10.1016\/j.annonc.2025.03.016_bib7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00120-024-02473-6","article-title":"[Non-clear cell renal cell carcinoma]","volume":"63","author":"Ahrens","year":"2024","journal-title":"Urologie"},{"issue":"8","key":"10.1016\/j.annonc.2025.03.016_bib8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.03.016_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10275","key":"10.1016\/j.annonc.2025.03.016_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.annonc.2025.03.016_bib11","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.03.016_bib12","unstructured":"NCCN Guidelines\u00ae Insights: Kidney Cancer, Version 3.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1440. Accessed January 14, 2025."},{"key":"10.1016\/j.annonc.2025.03.016_bib13","series-title":"Konsultationsfassung S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms","author":"Langer","year":"2024"},{"issue":"2","key":"10.1016\/j.annonc.2025.03.016_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.03.016_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004780","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-na\u00efve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)","volume":"11","author":"Atkins","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2025.03.016_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non\u2013clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.03.016_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.03.016_bib18","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/j.clgc.2020.02.009","article-title":"Multicentric analytical and inter-observer comparability of four clinically developed programmed death-ligand 1 immunohistochemistry assays in advanced clear-cell renal cell carcinoma","volume":"18","author":"Sommer","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"18","key":"10.1016\/j.annonc.2025.03.016_bib19","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.016_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2023.01.010","article-title":"Survival by depth of response and efficacy by international metastatic renal cell carcinoma database consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study","volume":"6","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.016_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","article-title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","volume":"20","author":"Mart\u00ednez Chanz\u00e1","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.03.016_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non\u2013clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.03.016_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2025.03.016_bib24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2025.03.016_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.03.016_bib26","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2022.0238","article-title":"Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)","volume":"8","author":"Procopio","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.03.016_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.03.016_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114121","article-title":"PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: results from a GETUG multicenter retrospective cohort","volume":"205","author":"Naffrichoux","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.016_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1773200","article-title":"Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients","volume":"9","author":"Zhang","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.016_bib30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-024-02059-y","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2025.03.016_bib31","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.3390\/ijms25073916","article-title":"Association between PD-L1 expression and the prognosis and clinicopathologic features of non-clear cell renal cell carcinoma","volume":"25","author":"Chraba\u0144ska","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.annonc.2025.03.016_bib32","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:14:21Z","timestamp":1762319661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0923753425001243"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.03.016","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}